The Role of MicroRNAS in Ankylosing Spondylitis

Medicine (United States)

Volumn 95, Issue 14, 2016, Pages

  Li, Zheng ^a   Wong, Sunny H ^b   Shen, Jianxiong ^a   Chan, Matthew T V ^b   Wu, William Ka Kei ^b  

^a PEKING UNION MEDICAL COLLEGE HOSPITAL   (China)

^b CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

[No Author keywords available]

Indexed keywords

MICRORNA; MICRORNA 124;

ANKYLOSING SPONDYLITIS; ARTICLE; CELL FUNCTION; CLINICAL FEATURE; CYTOKINE RESPONSE; DISEASE COURSE; EARLY DIAGNOSIS; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; HUMAN; IMMUNOCOMPETENT CELL; OSSIFICATION; OSTEOLYSIS; PATHOGENESIS; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; SACROILIAC JOINT; T LYMPHOCYTE; GENETICS; PHYSIOLOGY;

HUMANS; MICRORNAS; SPONDYLITIS, ANKYLOSING;

EID: 84964674914     PISSN: 00257974     EISSN: 15365964     Source Type: Journal    
DOI: 10.1097/MD.0000000000003325     Document Type: Article

References (47)

1. Yu H, Liu Y, Zhang L, et al. FoxO1 gene confers genetic predisposition to acute anterior uveitis with ankylosing spondylitis. Invest Ophthalmol Vis Sci. 2014;55:7970-7974.
2. Costello ME, Ciccia F, Willner D, et al. Intestinal dysbiosis in ankylosing spondylitis. Arthritis Rheumatol. 2014[Epub ahead of print].
3. Danve A, Reddy A, Vakil-Gilani K, et al. Routine Assessment of Patient Index Data 3 score (RAPID3) correlates well with Bath Ankylosing Spondylitis Disease Activity index (BASDAI) in the assessment of disease activity and monitoring progression of axial spondyloarthritis. Clin Rheumatol. 2015;34:117-124.
4. Svealv BG, Tang MS, Klingberg E, et al. Prevalence of diastolic dysfunction in patients with ankylosing spondylitis: a cross-sectional study. Scand J Rheumatol. 2015;44:111-117.
5. Chen J, Lin S, Liu C. Sulfasalazine for ankylosing spondylitis. Cochrane Database Syst Rev. (11):2014:CD004800.
6. Henriksson K, From J, Stratelis G. Patient-reported adherence to coprescribed proton pump inhibitor gastroprotection in osteoarthritis, rheumatoid arthritis, and ankylosing spondylitis patients using nonsteroidal anti-inflammatory drugs. Patient Prefer Adherence. 2014;8:1611-1617.
7. Lubrano E, Spadaro A, Amato G, et al. Tumour necrosis factor alpha inhibitor therapy and rehabilitation for the treatment of ankylosing spondylitis: a systematic review. Semin Arthritis Rheum. 2015;44:542-550.
8. Fan D, Liu L, Ding N, et al. Male sexual dysfunction and ankylosing spondylitis: a systematic review and metaanalysis. J Rheumatol. 2015;42:252-257.
9. Zhang P, Yu K, Guo R, et al. Ankylosing spondylitis: correlations between clinical and MRI indices of sacroiliitis activity. Clin Radiol. 2015;70:62-66.
10. Gao H, Li X, Wang C. Ankylosing spondylitis with idiopathic spinal cord herniation. Spine J. 2015;15:552-553.
11. Hou ZD, Xiao ZY, Gong Y, et al. Arylamine N-Acetyltransferase polymorphisms in Han Chinese patients with ankylosing spondylitis and their correlation to the adverse drug reactions to sulfasalazine. BMC Pharmacol Toxicol. 2014;15:64.
12. Liu Z, Zhang P, Dong J. Genetic variants of STAT4 are associated with ankylosing spondylitis susceptibility and severity in a Chinese Han population. Int J Clin Exp Med. 2014;7:5877-5881.
13. Dean LE, Jones GT, MacDonald AG, et al. Global prevalence of ankylosing spondylitis. Rheumatology (Oxford). 2014;53:650-657.
14. Haywood KL, Packham JC, Jordan K.P. Assessing fatigue in ankylosing spondylitis: the importance of frequency and severity. Rheumatology (Oxford). 2014;53:552-556.
15. Gan FY, Fei YY, Li MT, et al. The characteristics of patients having ankylosing spondylitis associated with Takayasu's arteritis. Clin Rheumatol. 2014;33:355-358.
16. Valente RL, Valente JM, de Castro GR, et al. Subclinical atherosclerosis in ankylosing spondylitis: is there a role for inflammation? Rev Bras Reumatol. 2013;53:377-381.
17. Jia C, Liu H, Li M, et al. Effects of icariin on cytokine-induced ankylosing spondylitis with fibroblastic osteogenesis and its molecular mechanism. Int J Clinical Exp Pathol. 2014;7:9104-9109.
18. Bond D. Ankylosing spondylitis: diagnosis and management. Nurs Stand. 2013;28:52-59quiz 60.
19. Li Z, Yu X, Shen J, et al. MicroRNA expression and its implications for diagnosis and therapy of gallbladder cancer. Oncotarget. 2015;6:13914-13924.
20. Yu X, Li Z. The role of MicroRNAs expression in laryngeal cancer. Oncotarget. 2015;6:23297-23305.
21. Li Z, Yu X, Shen J, et al. MicroRNA in intervertebral disc degeneration. Cell Prolif. 2015;48:278-283.
22. Yu X, Li Z, Liu J. MiRNAs in primary cutaneous lymphomas. Cell Prolif. 2015;48:271-277.
23. Luo X, Dong Z, Chen Y, et al. Enrichment of ovarian cancer stemlike cells is associated with epithelial to mesenchymal transition through an miRNA-Activated AKT pathway. Cell Prolif. 2013;46:436-446.
24. Bier A, Giladi N, Kronfeld N, et al. MicroRNA-137 is down-regulated in glioblastoma and inhibits the stemness of glioma stem cells by targeting RTVP-1. Oncotarget. 2013;4:665-676.
25. Yu X, Li Z, Shen J, et al. MicroRNA-10b promotes nucleus pulposus cell proliferation through RhoC-Akt pathway by targeting HOXD10 in intervetebral disc degeneration. PloS one. 2013;8:e83080.
26. Li Z, Yu X, Shen J, et al. MicroRNA expression and its clinical implications in Ewing's sarcoma. Cell Prolif. 2015;48:1-6.
27. Yu X, Li Z. MicroRNAs regulate vascular smooth muscle cell functions in atherosclerosis (review). Int J Mol Med. 2014;34:923-933.
28. Li M, Yu M, Liu C, et al. miR-34c works downstream of p53 leading to dairy goat male germline stem-cell (mGSCs) apoptosis. Cell Prolif. 2013;46:223-231.
29. Wang Z, Wang N, Liu P, et al. MicroRNA-25 regulates chemoresis-tance-Associated autophagy in breast cancer cells, a process modulated by the natural autophagy inducer isoliquiritigenin. Oncotarget. 2014;5:7013-7026.
30. Dong R, Liu X, Zhang Q, et al. miR-145 inhibits tumor growth and metastasis by targeting metadherin in high-grade serous ovarian carcinoma. Oncotarget. 2014;5:10816-10829.
31. Li Z, Lei H, Luo M, et al. DNA methylation downregulated mir-10b acts as a tumor suppressor in gastric cancer. Gastric Cancer. 2015;18:43-54.
32. Li Z, Yu X, Wang Y, et al. By downregulating TIAM1 expression, microRNA-329 suppresses gastric cancer invasion and growth. Oncotarget. 2015;6:17559-17569.
33. Li Z, Yu X, Shen J, et al. MicroRNA dysregulation in uveal melanoma: a new player enters the game. Oncotarget. 2015;6:4562-4568.
34. Li J, You T, Jing J. MiR-125b inhibits cell biological progression of Ewing's sarcoma by suppressing the PI3K/Akt signalling pathway. Cell Prolif. 2014;47:152-160.
35. Schirmer U, Doberstein K, Rupp AK, et al. Role of miR-34a as a suppressor of L1CAM in endometrial carcinoma. Oncotarget. 2014;5:462-472.
36. Chatzikyriakidou A, Voulgari PV, Georgiou I, et al. The role of microRNA-146a (miR-146a) and its target IL-1R-Associated kinase (IRAK1) in psoriatic arthritis susceptibility. Scand J Immunol. 2010;71:382-385.
37. Qi J, Hou S, Zhang Q, et al. A functional variant of pre-miRNA-196a2 confers risk for Behcet's disease but not for Vogt-Koyanagi-Harada syndrome or AAU in ankylosing spondylitis. Hum Genet. 2013;132:1395-1404.
38. Xu HY, Wang ZY, Chen JF, et al. Association between ankylosing spondylitis and the miR-146a and miR-499 polymorphisms. PloS one. 2015;10:e0122055.
39. Niu Z, Wang J, Zou H, et al. Common MIR146A polymorphisms in Chinese ankylosing spondylitis subjects and controls. PLoS One. 2015;10:e0137770.
40. Lai NS, Yu HC, Chen HC, et al. Aberrant expression of microRNAs in T cells from patients with ankylosing spondylitis contributes to the immunopathogenesis. Clin Exp Immunol. 2013;173:47-57.
41. Huang J, Song G, Yin Z, et al. Elevated miR-29a expression is not correlated with disease activity index in PBMCs of patients with ankylosing spondylitis. Mod Rheumatol. 2014;24:331-334.
42. Jiang Y, Wang L. Role of histone deacetylase 3 in ankylosing spondylitis via negative feedback loop with microRNA-130a and enhancement of tumor necrosis factor-1alpha expression in peripheral blood mononuclear cells. Mol Med Rep. 2016;13:35-40.
43. Hou C, Zhu M, Sun M, et al. MicroRNA let-7i induced autophagy to protect T cell from apoptosis by targeting IGF1R. Biochem Biophys Res Commun. 2014;453:728-734.
44. Xia Y, Chen K, Zhang MH, et al. MicroRNA-124 involves in ankylosing spondylitis by targeting ANTXR2. Mod Rheumatol. 2015;25:784-789.
45. Huang CH, Wei JC, Chang WC, et al. Higher expression of whole blood microRNA-21 in patients with ankylosing spondylitis associated with programmed cell death 4 mRNA expression and collagen cross-linked C-telopeptide concentration. J Rheumatol. 2014;41:1104-1111.
46. Zhao H, Wang D, Fu D, et al. Predicting the potential ankylosing spondylitis-related genes utilizing bioinformatics approaches. Rheu-matol Int. 2015;35:973-979.
47. Xu X, Araki K, Li S, et al. Autophagy is essential for effector CD8() T cell survival and memory formation. Nat Immunol. 2014;15:1152-1161.